AQST insider trading
NasdaqGM HealthcareAquestive Therapeutics, Inc.: insider trade history from SEC Form 4 filings.
About Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Company website: www.aquestive.com
AQST insider activity at a glance
FilingIQ tracks 249 insider transactions for AQST in filings since Jul 26, 2018. The most recent transaction is dated Sep 15, 2026.
Across the full history, 34 open-market purchases
and 35 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on AQST insider trades is 52.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest AQST Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for AQST?
- FilingIQ tracks 249 Form 4 insider transactions for AQST (Aquestive Therapeutics, Inc.), covering filings from Jul 26, 2018 onwards. 10 of those are dated within the last 90 days.
- Are AQST insiders net buyers or net sellers?
- Across the full Form 4 history for AQST, 34 transactions (14%) were open-market purchases and 35 (14%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does AQST insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is AQST in?
- Aquestive Therapeutics, Inc. (AQST) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $516.68M.
Methodology & sources
Every AQST insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.